JAQC

SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)

SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)

SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)

SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)

SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)

SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)

15-12G - Jupiter Acquisition Corp (0001817868) (Filer)

8-K - Jupiter Acquisition Corp (0001817868) (Filer)

25-NSE - Jupiter Acquisition Corp (0001817868) (Subject)

8-K - Jupiter Acquisition Corp (0001817868) (Filer)

Jupiter Acquisition announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the "Business Combination Agreement"). The special meeting of stockholders of Jupiter scheduled to reconvene on Thursday, December 28, 2023, at 12:00 p.m. Eastern Time, at which stockholders of Jupiter were to be asked to vote to approve the Business Combination Agreement and the business combination contemplated thereby, among other related matters, has been cancelled. Jupiter will redeem all of the outstanding shares of its Class A common stock issued as part of the units sold in Jupiter's initial public offering (the "IPO", and such shares,

VANCOUVER, BC, Dec. 19, 2023  /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Business Combination Agreement, by and among the Company, Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter"), 1427702 B.C. Ltd. ("TopCo") and Filament Merger Sub LLC, dated as of July 18, 2023 (as amended by the First Amendment to the Business Combination Agreement, the "Business Combination Agreement"), with respect to a proposed business combination between Filament and Jupiter (the "Proposed Business Combination"), has been terminated by the parties by mutual agreement.

Hobe Sound, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter") today announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the "Business Combination Agreement"). The special meeting of stockholders of Jupiter scheduled to reconvene on Thursday, December 28, 2023, at 12:00 p.m. Eastern Time, at which stockholders of Jupiter were to be asked to vote to approve the Business Combination Agreement and the business combination contemplated thereby, among other related matters, has been cancelled. Jupiter will redeem all of the outstanding shares of its Class A common stock i

VANCOUVER, BC, Dec. 18, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the special meeting of its securityholders held this Monday, December 18, 2023 at 9:30 a.m. (Vancouver time) (the "Special Meeting") to approve, among other things, the Company's proposed arrangement (the "Arrangement") under Part 9, Division 5 of the Business Corporations Act (British Columbia) was terminated. At the Special Meeting, the Arrangement Resolution attached to the management information circular of Filament dated November 7, 2023 (the "Circular") was not presented to the se

DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)

8-K - Jupiter Acquisition Corp (0001817868) (Filer)

DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)

Hobe Sound, FL, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter") today announced that it intends to reconvene and then adjourn, without conducting any business, the special meeting of stockholders of Jupiter (the "Business Combination Special Meeting") scheduled to reconvene on Tuesday, December 12, 2023, at 12:00 p.m. Eastern Time, until Monday, December 18, 2023, at 12:00 p.m. Eastern Time, as a completely virtual meeting conducted via live webcast, which will be available at https://www.cstproxy.com/jupiteracquisitioncorp/sm2023. At the Business Combination Special Meeting, once further reconvened, stockholders of Jupiter will be asked to vote

VANCOUVER, BC, Dec. 11, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, announces that the special meeting of its securityholders to be held this Monday, December 11, 2023 at 9:30 a.m. (Vancouver time) (the "Special Meeting") to approve, among other things, the Company's proposed arrangement (the "Arrangement") under Part 9, Division 5 of the Business Corporations Act (British Columbia) (the "Act") has been adjourned. The Special Meeting has been adjourned in acc

DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)

DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)

DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)

VANCOUVER, BC, Dec. 6, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, is pleased to announce that, further to its press release dated November 23, 2023, the Company has entered into a definitive securities purchase agreement (the "Securities Purchase Agreement") with Helena Global Investment Opportunities 1 Ltd. (the "Note Investor"), an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor ("Helena") and 1427702 B.C. Ltd. ("TopCo"), providing for up to USD$14.4 million in funding through the issuance of senior secured convertible notes (the "Notes" an

DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)

8-K - Jupiter Acquisition Corp (0001817868) (Filer)